Veratraldehyde (3,4-Dimethoxybenzaldehyde) Clinical Trials

Size	Price	Qty
500mg	USD 97

Clinical Trials

Multiple clinical trials evaluate therapeutic applications across oncology, cardiovascular health, and psychiatry, targeting heart failure, tricuspid valve disease, paraphilic disorders, and solid tumors including esophageal squamous cell, non-small cell lung, prostate, colorectal, and hepatocellular carcinomas. These early-stage Phase 1, Phase 2, and non-applicable phase studies are sponsored by academic institutions, health authorities, and pharmaceutical developers including Servier, Abbott, and Twinpig Biolab Inc. Recruitment statuses for these trials range from withdrawn to not yet recruiting.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT05312372	Withdrawn	Esophageal Squamous Cell Carcinoma	Institut de Recherches Internationales Servier\|ADIR a Servier Group company\|Servier	2025-05	Phase 1\|Phase 2
NCT04977310	Not yet recruiting	Heart Failure	STAVROS G DRAKOS\|Abbott\|University of Utah	2025-03-31	Not Applicable
NCT06400160	Not yet recruiting	NSCLC\|Prostate Cancer\|Colorectal Cancer\|Hepatocellular Carcinoma	Twinpig Biolab Inc.	2024-10	Phase 1\|Phase 2
NCT06404684	Not yet recruiting	Paraphilic Disorders	Region Stockholm	2024-10	Not Applicable
NCT06137807	Not yet recruiting	Tricuspid Regurgitation\|Tricuspid Valve Disease	P+F Products + Features USA Inc.\|P+F Products + Features GmbH\|Meditrial USA Inc.	2024-07	Not Applicable

(data from https://clinicaltrials.gov, updated on 2024-05-22)

Check the Veratraldehyde (3,4-Dimethoxybenzaldehyde) product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Veratraldehyde functions as a redox-active derivative that modulates cellular oxidative balance and downregulates downstream biochemical signaling cascades, leading to selective cytotoxicity and altered cell survival. This disruption of redox homeostasis underlies its potential therapeutic utility in clinical trial indications such as solid tumors, including esophageal squamous cell carcinoma and hepatocellular carcinoma, as well as heart failure.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).